• Colorectal and other GI cancers

Qinlock Generic Name & Formulations

General Description

Ripretinib 50mg; tabs.

Pharmacological Class

Tyrosine kinase inhibitor.

How Supplied


Generic Availability


Qinlock Indications


In adults with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Qinlock Dosage and Administration


Swallow whole. 150mg once daily until disease progression or unacceptable toxicity. Concomitant moderate CYP3A4 inducer (if unavoidable): give 150mg twice daily. Dose modifications: see full labeling.


Not established.

Qinlock Contraindications

Not Applicable

Qinlock Boxed Warnings

Not Applicable

Qinlock Warnings/Precautions


Risk of new primary cutaneous malignancies. Perform skin exams prior to initiation and during therapy. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Uncontrolled hypertension: do not initiate. Control BP prior to initiation; monitor and treat during therapy as appropriate. Cardiac dysfunction. Assess ejection fraction by echocardiogram or MUGA scan prior to initiation, during therapy, and as clinically indicated. Permanently discontinue if Grade 3/4 left ventricular systolic dysfunction occurs. Impaired wound healing: withhold for ≥1 week prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Safety of resuming therapy after resolution of wound healing complications has not been established. Photosensitivity: limit UV exposure during and for at least 1 week after discontinuation. Moderate or severe hepatic impairment. Severe renal impairment. Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for ≥1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥1 week after the last dose).

Qinlock Pharmacokinetics

See Literature

Qinlock Interactions


Potentiated by strong CYP3A4 inhibitors; monitor frequently. Antagonized by strong CYP3A4 inducers; avoid concomitant use. May be antagonized by moderate CYP3A4 inducers; avoid concomitant use; if unavoidable, increase dosing frequency (see Adult dose).

Qinlock Adverse Reactions

Adverse Reactions

Alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia, vomiting; lab abnormalities (eg, increased lipase, decreased phosphate).

Qinlock Clinical Trials

See Literature

Qinlock Note

Not Applicable

Qinlock Patient Counseling

See Literature